William Blair Starts Achaogen (AKAO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Bloom Energy shares fall on Oracle project halt
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Cowen Starts Achaogen (AKAO) at Outperform
April 8, 2014 8:08 AM EDTCowen initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $12.89 yesterday.
... MoreCredit Suisse Starts Achaogen (AKAO) at Outperform
April 7, 2014 7:31 AM EDTCredit Suisse initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreNeedham & Company Starts Achaogen (AKAO) at Buy
April 7, 2014 7:17 AM EDTNeedham & Company initiates coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $21.00.
Analyst Alan Car comments, "Lead drug plazomicin is under development for the treatment of infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). A Phase 3 trial... More
